Business
10 Things You Must Know About America’s Freestyle Skiing Sprint Sensation
Jaelin Kauf didn’t just ski; she attacked. On a day where the defending Olympic champion, Jakara Anthony, faltered under the immense pressure of the Italian Alps, Kauf remained a picture of technical violence and speed. Clocking the fastest time of the day at 24.88 seconds, Kauf’s aggressive line through the bumps and her signature “cork 720” aerial secured her a score of 80.77, second only to her teammate’s historic gold-medal run.
With this performance, Kauf becomes the first American woman to win back-to-back Olympic silver medals in moguls. Here are 10 essential facts you need to know about Jaelin Kauf’s incredible journey and today’s historic victory.
1. The 2026 Silver Medal & The “U.S. Sweep”
Today’s final in Livigno was the first time in Olympic history that two American women finished in the top two spots in freestyle skiing. Kauf’s silver, paired with Elizabeth Lemley’s gold, cemented a new era of American dominance. Despite being the veteran of the team, Kauf’s raw speed remained unmatched, forcing her younger rivals to push their technical limits just to keep pace.
2. Back-to-Back Olympic Silver (2022 & 2026)
Kauf has now matched her Silver Medal from the Beijing 2022 Games. In Beijing, she was the first American to medal in those Games, breaking a long drought for the U.S. moguls team. Her consistency across two vastly different Olympic cycles—one defined by COVID-19 isolation and the other by the roaring crowds of Italy—proves she is a generational talent.
3. “Robo-Kauf” Genetics: Born into Ski Royalty
Jaelin’s prowess is in her blood. Her parents, Scott Kauf and Patti Sherman-Kauf, were both professional mogul champions in the 1980s and 90s. Scott, nicknamed “Robo-Kauf” for his mechanical precision, was a five-time World Pro Mogul Tour champion. Patti was a three-time champion and an X-Games medalist in skicross. Unlike the Beijing Games, her parents were in the stands today in Livigno to watch her take silver in person.
4. The Fastest Woman on the World Cup Circuit
Kauf is universally recognized as the fastest woman on the moguls circuit. While many skiers focus on “absorbing” bumps to stay technical, Kauf “skis like a sprinter.” Her ability to maintain control while carrying unprecedented speed into the bottom air section is what separates her from the field and makes her the “time-score” benchmark for every competition.
5. The Dominant 2024–2025 “Triple Crown” Season
Leading up to these Olympics, Kauf had the best season of her career. In 2025, she became the first American since Hannah Kearney (2015) to win all three FIS Crystal Globes: the Moguls globe, the Dual Moguls globe, and the Overall Freestyle globe. She won 8 of 16 World Cup events last season, doubling her career win total in a single calendar year.
6. 2025 Dual Moguls World Champion
In March 2025, Kauf finally broke her “silver streak” at major championships by winning the Gold Medal in Dual Moguls at the FIS Freestyle World Championships in St. Moritz. This victory established her as the heavy favorite for the newest Olympic discipline.
7. Education: The University of Utah
While competing at the highest level, Kauf has been pursuing a degree in Environmental and Sustainable Studies at the University of Utah. She has used her platform to advocate for climate action through organizations like Protect Our Winters, highlighting the direct threat rising temperatures pose to the mountain communities she calls home.
8. The “Deliver the Love” Philosophy
Glued to the back of Kauf’s helmet is her personal motto: “Deliver the Love.” It serves as a reminder to prioritize the joy of skiing over the crushing pressure of the podium. After her run today, she embraced Elizabeth Lemley, personifying the mentorship and sportsmanship she has brought to the U.S. Ski Team for over a decade.
9. Technical Mastery: The Signature Cork 720
In today’s final, Kauf’s “top air” was a high-consequence cork 720 (two full rotations while off-axis), a trick that once gave her trouble in earlier qualifiers. Her ability to nail the landing and immediately transition back into a high-speed mogul line is why she remains a “judging favorite” for both air and turns.
10. The Mission Isn’t Over: Dual Moguls Debut
While the individual event is finished, Jaelin Kauf’s 2026 Olympic story has one chapter left. On Saturday, February 14, she will compete in the Olympic debut of Dual Moguls. As the reigning World Champion in this head-to-head format, Kauf is the odds-on favorite to finally secure the one thing missing from her trophy case: Olympic Gold.
Milano Cortina 2026: Women’s Moguls Final Results (Feb 11)
| Rank | Athlete | Country | Score |
| 1 (Gold) | Elizabeth Lemley | USA | 82.30 |
| 2 (Silver) | Jaelin Kauf | USA | 80.77 |
| 3 (Bronze) | Perrine Laffont | FRA | 78.00 |
Center will accelerate functional mushroom product development.
The closures have been announced days after Santander said it would shut branches.
Instagram’s longtime lead Adam Mosseri arrived on Wednesday at a courtroom in Los Angeles.
Citri-Fi Pro may replace up to 75% of acacia gum in beverages.
A basketball finds nothing but net during practice before a 2024 NCAA Tournament game at PPG Paints Arena in Pittsburgh.
Charles LeClaire | Reuters
Prediction markets saw strong results from the Super Bowl, but it was just an appetizer for a banquet of sporting events in 2026 that are expected to drive surging volumes in event contracts.
Kalshi saw record downloads during Super Bowl week, up 1,544% from the same time period last year, according to a report from market intelligence firm Sensor Tower. Daily active users jumped more than 1,100% to nearly 2 million on the day of the big game, the firm said.
That was almost three times the daily active users on sportsbook BetMGM, co-owned by MGM and Entain, which had 81% growth to 680,000 daily active users. Polymarket reported 59,000 daily active users and 264% growth over the previous year.
More than $1 billion was traded on Kalshi for the Super Bowl, up 2,700% according to the company. Founder and CEO Tarek Mansour told CNBC Tuesday that consumers are drawn by having lots of trading options for the game in one place.
“Our culture markets were huge this weekend. You know, ‘What [Bad] Bunny was going to perform’ was over $100 million in trading,” he said.
Though prediction markets enable users to buy event contracts for a wide swath of financial, weather, pop culture and other events, sports have been driving the action and the profits.
Robinhood CEO Vlad Tenev is pushing back against any investor concerns the Super Bowl was as good as it gets for trading on sports prediction markets.
“What we’re actually seeing is surprising us,” Tenev said on his company’s fourth-quarter earnings call on Tuesday. “In January, for instance, NBA contracts surpassed NFL in trading activity on our platform.”
Major sports events keep rolling, with the Winter Olympics offering a variety of betting options through Feb. 22. This weekend, fans will also get an eyeful during the NBA All-Star Weekend.
March brings college basketball madness, with the NCAA Tournament taking off with Selection Sunday on March 15. The entire tournament typically brings in more gambling dollars than Super Bowl.
And then there’s the World Cup, kicking off 104 games in mid-June.
Kalshi has been aggressive in marketing, outspending Polymarket in the United States by about 19 times and outspending DraftKings by about 35%, according to Sensor Tower estimates.
Still, the American giants in sports betting remain dominant. DraftKings saw 5 million daily active users for the Super Bowl and FanDuel had 4.2 million, according to the Sensor Tower data.
The CEOs of sportsbook market leaders FanDuel and DraftKings both told CNBC just before the game that they don’t see any cannibalization of their traditional sports betting business. They instead see real opportunity with sports and event contracts in states that haven’t legalized sports wagering.
Tenev said events contracts are the “fastest growing business in the company’s history.” Robinhood reported a 300% rise in “other revenue,” which is largely comprised of event contracts.
And the growth is accelerating. Robinhood reported 12 billion event contracts in 2025, and it’s already seen 4 billion contracts so far in 2026.
Disclosure: CNBC and Kalshi have a commercial relationship that includes a minority investment.
Meeting the challenges of switching to colors perceived as natural.
Payne Capital Management President Ryan Payne explains why tech earnings remain strong despite a recent dip and how AI hiring could help offset a wave of baby boomer retirements on ‘Mornings with Maria’.
Amazon is expanding its same-day prescription delivery service to nearly 4,500 U.S. cities and towns by the end of 2026, adding about 2,000 new communities, including statewide coverage in Idaho and Massachusetts.
The move deepens Amazon’s push into the prescription drug market, which it entered in 2018 through its acquisition of PillPack. The company is positioning faster delivery and subscription pricing as competitive advantages against traditional pharmacy chains.
Amazon said the expansion comes as pharmacy closures, staffing shortages and transportation barriers make it harder for some patients – particularly in rural and remote areas – to access medications.
AMAZON TO CUT 16,000 ROLES AS IT LOOKS TO INVEST IN AI, REMOVE ‘BUREAUCRACY’
“Patients shouldn’t have to choose between speed, cost, and convenience when it comes to their medication, regardless of where they live,” said John Love, vice president of Amazon Pharmacy. “By combining our pharmacy expertise with our logistics network, we’re removing critical barriers and helping patients start treatment faster—setting a new standard for accessible, digital-forward pharmacy care.”
Boxes lie on a conveyor belt during Cyber Monday at Amazon’s fulfillment center in Robbinsville, New Jersey, U.S., Dec. 2, 2024. (Eduardo Munoz/Reuters)
The company said it improved delivery speeds across all 50 states and Washington, D.C., in 2025. Faster shipping is expanding into rural areas, including remote Alaska towns and parts of the Navajo Nation, where the nearest pharmacy can be nearly an hour away.
AMAZON SPEEDS UP PRESCRIPTION DELIVERY IN NYC, LA
Close-up of an Amazon Pharmacy shipping label on a cardboard box, Reliez Valley, California, Feb. 9, 2025. (Smith Collection/Gado/Getty Images)
Amazon is also integrating pharmacy services with One Medical, the primary care provider it acquired in 2023. Some One Medical patients can pick up prescriptions at in-clinic kiosks, and the company began filling select prescriptions at those electronic kiosks in December. One Medical operates on a $199 annual membership model.
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| AMZN | AMAZON.COM INC. | 203.29 | -3.67 | -1.77% |
In October, Amazon partnered with WeightWatchers to supply medications, including injectable GLP-1 obesity treatments, to its members. Amazon Pharmacy also offers the oral GLP-1 Wegovy pill.
Amazon packages seen on a conveyor belt at a warehouse facility. (Luke Sharrett/Bloomberg via Getty Images / Getty Images)
The company continues to promote cost-saving programs, including Prime Rx discounts of up to 80% on generics and 40% on brand-name drugs for uninsured members, as well as RxPass, a $5-per-month subscription available in 48 states for more than 50 common medications.
CLICK HERE TO GET FOX BUSINESS ON THE GO
Amazon said its expanded same-day and next-day delivery network is aimed at patients managing both acute and chronic conditions.
Reuters contributed to this report.
Novo Nordisk President and CEO Mike Doustdar joins ‘Mornings with Maria’ to discuss the launch of the first GLP-1 weight-loss pill in the U.S., the lawsuit against Hims & Hers and talks with the Trump administration on drug pricing.
GLP-1 weight-loss drugs are now the focus of a heated legal battle, with a leading drugmaker warning that copycat versions pose a risk to patient safety.
“When you go and try to source raw materials from China or unknown sources, put it in an injection, and sell knockoff medication, there is something wrong with this,” Mike Doustdar, president and CEO of Novo Nordisk, told FOX Business’ Maria Bartiromo.
Novo, best known for its blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy, has filed a lawsuit against Hims & Hers Health, accusing the telehealth company of selling compounded, unapproved versions of its semaglutide-based medications, including a copycat version of its newly launched daily pill.
Doustdar said the introduction of the oral option broadens access for patients who are reluctant to use injections, but he sharply criticized what he described as widespread “mass compounding” of GLP-1 drugs by telehealth firms.
DANGEROUS ‘GRAY-MARKET’ WEIGHT-LOSS DRUGS FLOODING US AS EXPERTS WARN OF RISKS
A woman injects a GLP-1 injection into her stomach in this undated photo taken at an undisclosed location. (iStock / iStock)
“Compounding is supposed to be for a few individuals that have, let’s say, allergic reactions to the real medicine,” he said. “But this mass compounding — it’s quite unbelievable that it has gotten to this point.”
He added that Novo has filed multiple lawsuits against compounders, arguing that the launch of a compounded pill version crossed a line.
“I think the nail in the coffin, as they say, was when they completely made a new drug — the pill — a compounded version of it and basically tried to introduce that to the market,” he said. “That’s where we felt enough is enough.”
TARGET BEEFS UP PROTEIN, SUPPLEMENT OFFERINGS, CAPITALIZING ON WEIGHT LOSS DRUG TREND
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah on Thursday, Jan. 15. (George Frey/Bloomberg via Getty Images / Getty Images)
Hims & Hers fired back against Novo Nordisk in a statement issued to multiple outlets this week, blasting the legal move as “a blatant attack by a Danish company on millions of Americans who rely on compounded medications for access to personalized care” and accusing “Big Pharma” of “weaponizing the U.S. judicial system to limit consumer choice.”
“This lawsuit attacks more than just one medication or company – it directly assaults a well-established, vital component of U.S. pharmacy practice that has improved patient care for everything from obesity to infertility to cancer,” a representative for the company said, per the New Jersey business publication NJBIZ.
The company also cited its history of providing “safe access to personalized healthcare to millions of Americans,” adding that it will “continue to fight to provide choice, affordability and access.”
AIRLINES HAVE 580 MILLION REASONS TO LIKE GLP-1 WEIGHT-LOSS DRUGS, ANALYSIS FINDS
The New York Stock Exchange with a Hims & Hers Health, Inc. banner is pictured as a person runs past in the Manhattan borough of New York City, New York on Jan. 21, 2021 (Reuters/Carlo Allegri / Reuters)
For some time, patients seeking GLP-1 therapy for conditions such as obesity, type 2 diabetes, fatty liver disease and metabolic syndrome have sought compounded alternatives after facing insurance roadblocks that created cost challenges for brand-name medications.
Doustdar said Novo’s recent cost reductions have eliminated the need for copycat drugs due to what he described as pricing similarities between branded and compounded versions.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
Fox News senior medical analyst Dr. Marc Siegel joins ‘Mornings with Maria’ to break down the new FDA-approved weight loss pill, concerns over cost and safety and how GLP-1 drugs could transform obesity care.
However, when Hims & Hers briefly launched its compounded oral semaglutide, it was marketed at about $49 per month as an introductory price and around $99 per month thereafter, lower than Novo’s FDA-approved oral Wegovy, which launched at roughly $149 per month and can cost up to $299 at higher doses under self-pay pricing.
Hims & Hers later pulled the oral compounded medication from its platform following legal threats from Novo and scrutiny from federal regulators.
Novo Nordisk CEO Mike Doustdar on Wednesday said the company is aiming to capture around 15 million new patients, at least initially, when Medicare starts covering obesity treatments for the first time later this year.
Around 67 million Americans are covered by Medicare, but “when you take a look at specifically our products and the target group, I think around 15 million people would be a good number to target,” he told CNBC in an interview.
Medicare is slated to start covering obesity medicines for the first time later this year under the landmark “most favored nation” drug pricing deals that Novo and its chief rival Eli Lilly struck with President Donald Trump in November.
Health experts say the long-awaited coverage could broaden the market for the medicines and spur more private insurers to cover them. Some experts estimate that 20 million to 30 million Medicare patients are suffering from obesity and related conditions.
Doustdar said Medicare coverage, along with the launch of Novo’s new obesity pill and other factors, should help the company gradually boost prescription volumes and offset lower prices in the U.S. following that agreement with Trump.
But he said he doesn’t expect Medicare access to obesity treatments to open up overnight.
“Now, it would be great if we could find a way to get access very, very fast. But I think that would be a bit naive,” Doustdar said, pointing to the slow adoption seen among eligible patients with commercial insurance.
It’s a slightly more conservative tone on the initial impact of Medicare coverage compared to Lilly, which has cited that coverage as a key tailwind to its guidance this year. Last week, Lilly said it expects Medicare coverage to come online by July.
Meanwhile, Doustdar said Novo is in the midst of negotiations with the government on “exactly which month, which week that is going to be opening.”
Closing the market share gap
Novo is under pressure to claw back market share in the booming GLP-1 space from Lilly and cheaper, compounded copycats. Last week, Lilly said its share of the U.S. obesity and diabetes drug market increased to 60.5% in the fourth quarter, while Novo’s was 39.1%.
Novo has also highlighted a gap in the “preference share” for its weight loss treatment Wegovy versus Lilly’s rival injections. In the U.S., Novo estimates that between 7 and 8 patients out of 10 go to Lilly.
When asked how Novo plans to close that gap, Doustdar said one way to do so is “to do better on the pill.” The company’s Wegovy obesity pill has a head start compared to Lilly’s upcoming oral drug, orforglipron, which is expected to win approval from the Food and Drug Administration during the second quarter.
Mike Doustdar, left, CEO of Novo Nordisk, and David Ricks, CEO of Eli Lilly, listen as President Donald Trump speaks in the Oval Office during an event about weight-loss drugs on Nov. 6, 2025.
Andrew Caballero-Reynolds | Afp | Getty Images
Doustdar said Novo’s pill is slightly more effective than Lilly’s based on separate clinical trials, showing 16.6% weight loss compared to 12.4% with Lilly’s oral drug.
“If you use these two numbers, basically you have a 40% difference between the efficacy of these pills,” he said. “I think this is going to be a very main, main selling point of the pill.”
But Doustdar also pointed to the upcoming approval and launch of a higher dose – 7.2 milligram – of Wegovy that could help win market share from Lilly’s obesity treatment Zepbound.
That higher dose helps patients lose around 21% of their weight, which is “very much on par” with the highest dose of Zepbound, he said. Zepbound’s higher efficacy has been a key factor in driving more patients and prescribers away from choosing Wegovy, which has shown around 15% weight loss on average in clinical trials.
“When that comes to the market, my thought, my wish, my hope is that people will realize, OK, now we have two products with similar efficacy,” he said.
Trump meets Netanyahu, with US-Iran nuclear diplomacy topping agenda
No Bitcoin Bailout – Just the Royal Express Elevator Down
Would-be armed robber targeted Teesside University student
M2 Ingredients opens innovation center
Smart energy pays enters the US market, targeting scalable financial infrastructure
Software stocks enter bear market on AI disruption fear with ServiceNow plunging 10%
Wikipedia volunteers spent years cataloging AI tells. Now there’s a plugin to avoid them.
-
Politics3 days agoWhy Israel is blocking foreign journalists from entering
-
Sports5 days agoJD Vance booed as Team USA enters Winter Olympics opening ceremony
-
NewsBeat2 days agoMia Brookes misses out on Winter Olympics medal in snowboard big air
-
Business3 days agoLLP registrations cross 10,000 mark for first time in Jan
-
Tech5 days agoFirst multi-coronavirus vaccine enters human testing, built on UW Medicine technology
-
Tech15 hours agoSpaceX’s mighty Starship rocket enters final testing for 12th flight
-
NewsBeat3 days agoWinter Olympics 2026: Team GB’s Mia Brookes through to snowboard big air final, and curling pair beat Italy
-
Sports3 days agoBenjamin Karl strips clothes celebrating snowboard gold medal at Olympics
-
Sports4 days ago
Former Viking Enters Hall of Fame
-
Politics3 days agoThe Health Dangers Of Browning Your Food
-
Sports5 days ago
New and Huge Defender Enter Vikings’ Mock Draft Orbit
-
Business3 days agoJulius Baer CEO calls for Swiss public register of rogue bankers to protect reputation
-
NewsBeat5 days agoSavannah Guthrie’s mother’s blood was found on porch of home, police confirm as search enters sixth day: Live
-
Business3 days agoCostco introduces fresh batch of new bakery and frozen foods: report
-
Business6 days agoQuiz enters administration for third time
-
Crypto World1 day agoBlockchain.com wins UK registration nearly four years after abandoning FCA process
-
Crypto World1 day agoU.S. BTC ETFs register back-to-back inflows for first time in a month
-
NewsBeat2 days agoResidents say city high street with ‘boarded up’ shops ‘could be better’
-
Sports2 days ago
Kirk Cousins Officially Enters the Vikings’ Offseason Puzzle
-
Crypto World1 day agoEthereum Enters Capitulation Zone as MVRV Turns Negative: Bottom Near?